上市捷报丨沙利文助力杭州阿诺生物医药科技有限公司成功赴美上市(NASDAQ: ANL)

Hangzhou Anuo Biomedical Technology Co., Ltd. (Stock Code:NASDAQ:ANL) on2023year9month29We successfully logged into NASDAQ today. The company is a global biopharmaceutical company in clinical-stage development, with R&D and clinical operation centers located both in China and the US. Through the models of 'joint innovation' and 'independent research and development', we have built multiple global product pipelines, including:AN2025 (buparlisib)acquiredFDAThe fast-track qualification, when used in combination with paclitaxel, is expected to become a treatmentPD-1Second-line recurrence or metastasis after failureHNSCCThe first drug, which is being developed at multiple global centersIIIPhase I clinical trial;AN0025 (palupiprant)It is a therapeutic approach that aims to treat solid tumors by modulating the tumor microenvironmentEP4Antagonist, currently in collaboration withKeytruda^® Combined treatment for patients with multiple solid tumorsibclinical trial phase;AN4005An orally administered small molecule independently developedPD-L1Inhibitor, currentlyIPhase clinical trials are being conducted simultaneously in China and the United States to determine safety, tolerability, and recommended2Periodic dose(RP2D).Frost & SullivanFrost & SullivanFrost & Sullivan, hereinafter referred to as 'Frost & Sullivan', provides exclusive industry advisory services for the listing of Anuo Biopharmaceutical Technology Co., Ltd. We hereby extend our warmest congratulations on its successful listing.

Hangzhou Anuo Biomedical Technology Co., Ltd. (hereinafter referred to as 'Anuo Medicine') was established in2023year9month29Successful listing on the day, issuance scale461.410,000 sharesADSThe pricing is RMB 10.00 per share23US dollar, expected to reach a maximum1.061US$100 million raised, of which5,750$10,000,000 from public offerings (excluding underwriting discounts, commissions, and issuance expenses, and without considering the potential exercise of underwriters' over-allotment options),4,000$10,000,000 came from private placements during the same period.860$10,000,000 was raised from the full exercise of the over-allotment rights.

During the process of listing in the US this time, Frost & Sullivan mainly undertook the following tasks: helping the issuer accurately and objectively understand its positioning in the target market, using objective market data to discover, support and highlight the issuer's competitive advantages, assisting the issuer, sponsor and other professional intermediary institutions in completing the writing of relevant parts of the prospectus (such as the overview, competitive advantages and strategy, industry overview, business and other important chapters), and assisting the issuer in completing theSECCommunication with investors, helping them quickly understand the market ecosystem and competitive landscape, assisting issuers in completingSECFeedback on industry-related issues, etc.

Investment highlights

The company has a rich pipeline of products, including multiple innovative candidate drugs targeting a range of tumor indications;

The company has secured solid Phase II data to ensure successful registration;

The company targets unmet medical needs, possessing a huge potential market size;

The company has strong R&D capabilities and has established two drug discovery platforms, namelyPAINT-2D™andANEAT-Id™;

The company has a sustainable patent portfolio in key countries and regions;

The company has the participation of senior industry professionals and strong shareholder support.

According to the Frost & Sullivan report, the company:

AN2025Currently, it is the fastest progressing clinical treatment for relapsed/Metastatic head and neck squamous cell carcinomaPI3KInhibitors, which are only available globallyIIIPhase clinical trial.

AN0025can be increasedCD8+Cell activity, as well asTThe cellular immune response against tumors potentially alters the immunosuppressive characteristics of the tumor microenvironment and addresses unmet needs in the treatment of various cancer types.

AN2025,AN0025The clinical study of atezolizumab-trastuzumab-herceptin triple therapy is the first in the industry to be conducted for the treatment of advanced solid tumorsPI3Kinhibitor,EP4Antagonist and checkpoint inhibitor combination therapy represents a potential novel treatment strategy that is expected to address the currentPD-1/PD-L1Problems such as no response or low response rate to inhibitor therapy exist.

AN4005An orally administered small molecule developed in-house by the companyPD-L1Inhibitors are expected to achieve many benefits over antibodies, such as being suitable for oral administration, having lower production costs, higher tumor penetration, and being non-immunogenic. This could potentially solve the problem of increasing immune-related adverse events in current antibody-based therapies.

In the field of oncology treatment, Frost & Sullivan has served companies such as BeiGene, Innovent Biologics, Junshi Biosciences, Rongchang Biosciences, and Kangfang Biosciences.

View the full prospectus of Anuo Medicine

Frost & Sullivan integrates the globe.62years of consulting experience,25Frost & Sullivan wholeheartedly serves the booming Chinese market, with a global perspective to help clients accelerate their business growth and achieve industry-leading benchmarks in terms of growth, innovation, and leadership. The Greater Health Industry is one of the core areas of focus for Frost & Sullivan's research. Recently20For many years, the Frost & Sullivan team has provided financing and financial advisory services to hundreds of outstanding domestic and international biopharmaceutical, medical device, healthcare services, and internet healthcare companies.IPO listingIndustry consulting, strategic consulting, management consulting, and other services. Successful listing cases include: Neusoft Xikang （9686.HK), Youzhiyou2496.HK), Yiming Angke 1541.HK ), Colombo Bay6 990.HK), LaiKai Medicine 2105.HK), Kedite Group2487.HK), Lvz Bio2480.HK), Meis Health 2415.HK), Yaohua MedicinePHECR), Zhongjin Medical （NASDAQ:ZJYL), Yisheng Biology NASDAQ:YS ), Beautiful Countryside 2373.HK), Kangfeng Biology6922.HK), Bao'an Biology6955.HK), Ideasight1244.HK), Meihao Medical1947.HK), Gaoshi Medical (2407.HK), Lepu Xintai2291.HK), Genstar Biotech9877.HK), HealthyuanJCARE.SW), Leopu MedicalLEPU.SW), DINGDANG HEALTH9886.HK), Baidu Map Suggest (2315.HK), Zhiyun Health9955.HK), MeinGene6667.HK),Prenetics（PRE.NASDAQ), Yunkang Group2325.HK), Ruike Biotechnology2179.HK), Leepu Biotech2157.HK), Clear Medical (1406.HK), Baisinkan2185.HK), Yonghe Medical (2279.HK), Kailaiying6821.HK), Beihai Kangcheng1228.HK), Gusheng Hall2273.HK), Eagle Eye Technology2251.HK), Clover Biotechnology2197.HK), minimally invasive robots2252.HK), and Yuhui Kaiman2256.HK), Kunbo Medical (2216.HK), Xianruida6669.HK), Kangsheng Global9960.HK), Medical Pulse Connect (2192.HK), Tengsheng Bo medicine2137.HK), Conoco (2162.HK), Chaogju Eye Hospital2219.HK), Guichuangtong Bridge2190.HK), and Huang Medicine0013.HK), Keji Pharmaceutical2171.HK), Zhaoke Eye Hospital6622.HK), Nature MedicineUPC.NASDAQ), Sino Biologics (6600.HK), Zhaoyan New Drugs6127.HK), Novo Nordisk Health (6606.HK), Tianyan PharmaceuticalADAG.NASDAQ), Beikang Medical (2170.HK), Jianbimiao Miao Miao2161.HK), Minimally Invasive Cardiac Angioplasty (2160.HK), Ruili Medical Beauty2135.HK), Jiake Pharmaceutical1167.HK), and Bopan Medicine2142.HK), JD Health6618.HK), Deqi Medicine6996.HK), Rongchang Biology9995.HK), WuXi AppTec Genomics (2126.HK), Sinobiopharmaceuticals2096.HK), Yunding Xinyao1952.HK), Harvest Biotech6998.HK), ZaiDi Pharma9688.HK), Ocumivir1477.HK), Yongtai Biology6978.HK), Hype Pharma9989.HK), Kechuang Pharmaceutical9939.HK), Peijia Medical (9996.HK), Kangfang Biology9926.HK), Novo Nordisk China (9969.HK), Celestial BeingsIMAB.NASDAQ), Kanglonghua Cheng3759.HK), China Antibody3681.HK), Dongyao Pharmaceutical1875.HK), Yasheng Medicine6855.HK), Fosun Pharma (2696.HK), Hansoh Pharmaceutical3692.HK), Mabotech2181.HK), Founder Holdings1521.HK), Viva Biology1873.HK), CStone Pharmaceuticals2616.HK), Junshi Biology1877.HK), WuXi AppTec (2359.HK), Innovent Biologics1801.HK), Hualing Medicine2552.HK), BeiGene (6160.HK), Gelifarmaceuticals1672.HK), WuXi AppTec Biologics2269.HK), China Resources Medicine3320.HK), Yakult Biopharmaceuticals2633.HK), and Huangzhong China MedicineHCM.NASDAQ), Biotechnology1548.HK),BBILife Sciences1035.HK) and so on. According to the number of submission items, the Frost & Sullivan healthcare team is involved in medicalIPO listingMaintain an absolute leading position,2018till2022Year after year, it has always ranked first in market share.

since2019year7Since the initial listing of the first batch of companies on the Sci-tech Innovation Board, Frost & Sullivan reports have also been widely cited in the prospectuses of leading Sci-tech Innovation Board-listed companies, including: Fuerjia 301371.SZ), Hybrid Integration688249.SH), Wuxi Rilian688531.SH), Maolai Optics688502.SH), Kangwe Century688426.SH), coastal protein688137.SH), Novo Nordisk China (688428.SH), OPUMAI BIOLOGY688293.SH), minimally invasive electrophysiology688351.SH), Mengke Pharmaceutical688373.SH), Yifang Biology688382.SH), Jicui Pharmaceutical Health (688046.SH), Haiscot Biopharmaceuticals688302.SH), Rongchang Biology688331.SH), Rendu Biology688193.SH), Capital Pharmaceutical Holdings (688197.SH), and Yuanbiotech (688238.SH), YASIN Security688225.SH), Xidiwei688173.SH), MyWay Biotechnology688062.SH), Yarong Medicine688176.SH), BeiGene (688235.SH), Jiahemeikang688246.SH), DiZhe Medicine688192.SH), Novozymes688105.SH), Chengda Biology688739.SH), Gecko Micro688728.SH), Huaxi Biology688363.SH), Junshi Biology688180.SH), Zhejiang Genomics & Therapeutics Co., Ltd.688266.SH), Bai'ao Tai688177.SH), SinoCell (688520.SH) and others are considered one of the most powerful, professional, and influential industry research institutions in the industry. We hope to work with enterprises to understand industry trends, seize development opportunities, jointly promote innovation and upgrading of China's big health industry, and build a healthy future.